Trevor Baglin
Private Equity Investor bij Medicxi Ventures (Jersey) Ltd.
Profiel
Trevor is a Venture Advisor in the Medicxi investment team.
He co-founded XO1 (acquired by Janssen Pharmaceuticals) and Apcintex (acquired by Centessa Pharmaceuticals).
He is Chief Medical Officer for Apcintex and Z Factor (Centessa Companies).
Prior to joining Medicxi he was a clinician at Cambridge University Hospitals where he was also Director of Investigative Sciences.
His main research interests were in personalised risk profiling, developed from studying the gene-environment interaction leading to thrombosis, and the molecular basis of blood coagulation, which led to his interest in drug discovery and development.
He has published more than 300 clinical and scientific papers and led the production of many national and international guidelines.
Trevor served as President of the British Society for Haematology, President of the British Society for Haemostasis and Thrombosis and was a Founder of the European Congress for Thrombosis and Haemostasis.
He qualified in Medicine from Manchester University, was awarded his PhD from the University of Birmingham and Doctor of Medical Science from Cambridge University.
Actieve functies van Trevor Baglin
Bedrijven | Functie | Begin |
---|---|---|
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Private Equity Investor | 01-01-2017 |
Eerdere bekende functies van Trevor Baglin
Bedrijven | Functie | Einde |
---|---|---|
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Corporate Officer/Principal | - |
SuperX Ltd.
SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Oprichter | - |
XO1 Ltd.
XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Oprichter | - |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Oprichter | - |
Opleiding van Trevor Baglin
University of Birmingham | Doctorate Degree |
University of Cambridge | Graduate Degree |
The University of Manchester | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
SuperX Ltd.
SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
XO1 Ltd.
XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Health Services |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Health Technology |